|Dr. Seth Lederman||Co-Founder, Pres, CEO & Chairman||1.07M||N/A||1958|
|Mr. Bradley Saenger CPA, CPA||CFO & Treasurer||586.16k||N/A||1974|
|Dr. Gregory M. Sullivan M.D.||Chief Medical Officer & Sec.||676.2k||N/A||1966|
|Mrs. Jessica Edgar Morris||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Ronald R. Notvest||Exec. VP of Commercial Planning and Devel.||N/A||N/A||N/A|
|Dr. Herbert W. Harris||Exec. VP of Translational Medicine||N/A||N/A||N/A|
|Dr. Daniel J. Clauw M.D.||Consultant||N/A||N/A||N/A|
|Dr. R. Michael Gendreau||Consultant||N/A||N/A||1956|
Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute, Columbia University, the University of Alberta, and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.
Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.